Valuable Serum Markers in Pulmonary Alveolar Proteinosis

Objective Several serum markers were reported to reflect the severity of pulmonary alveolar proteinosis (PAP). The aim of this study is to investigate a reliable and facile marker to access and monitor the clinical course of PAP in a large cohort. Methods PAP patients from January 2010 to June 2018 were enrolled. Hospital records were used as data sources. The levels of various serum indicators were detected. We evaluated the correlation between pulmonary function test results and clinical variables. Results Diffusion capacity for carbon monoxide (DLCO) level was positively correlated with the level of high-density lipoprotein cholesterol (HDL-C) (P < 0.05) in 122 patients of PAP at baseline. The levels of HDL-C and DLCO significantly increased while carcinoembryonic antigen (CEA), CYFRA21-1, neuron-specific enolase (NSE), and lactic dehydrogenase (LDH) levels decreased six months after granulocyte-macrophage colony-stimulating factor (GM-CSF) inhalation therapy between 14 patients with PAP. Nevertheless, the increased DLCO was significantly correlated with decreased CEA (r = ‐0.579, P = 0.031) and CYFRA 21-1 (r = ‐0.632, P = 0.015). In 10 PAP patients without GM-CSF inhalation therapy, HDL-C and DLCO significantly decreased while NSE and LDH levels increased after six months of follow-up. The decreased DLCO was significantly correlated with increased LDH (r = ‐0.694, P = 0.026). Conclusions Serum CEA, CYFRA21-1, and LDH are valuable serum markers for the evaluation of disease activity of PAP and may predict the response to treatment of PAP.

[1]  Y. Inoue,et al.  Pulmonary alveolar proteinosis. , 2004, Nature reviews. Disease primers.

[2]  W. Hager,et al.  and s , 2019, Shallow Water Hydraulics.

[3]  R. Sarpong,et al.  Bio-inspired synthesis of xishacorenes A, B, and C, and a new congener from fuscol† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc02572c , 2019, Chemical science.

[4]  B. Trapnell,et al.  Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis , 2018, Nature Communications.

[5]  S. Leroy,et al.  Rituximab for auto-immune alveolar proteinosis, a real life cohort study , 2018, Respiratory Research.

[6]  B. Trapnell,et al.  Pulmonary Alveolar Proteinosis Syndrome. , 2016, Clinics in chest medicine.

[7]  C. Tinelli,et al.  Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures , 2016, Orphanet Journal of Rare Diseases.

[8]  J. Letheulle,et al.  [Pulmonary alveolar proteinosis]. , 2014, Revue des maladies respiratoires.

[9]  Y. Inoue,et al.  CYFRA 21‐1 as a disease severity marker for autoimmune pulmonary alveolar proteinosis , 2014, Respirology.

[10]  V. Tormey,et al.  Pulmonary alveolar proteinosis: report of two cases in the West of Ireland with review of current literature , 2014, Irish Journal of Medical Science.

[11]  Shencun Fang,et al.  Elevated tumor markers in patients with pulmonary alveolar proteinosis , 2013, Clinical chemistry and laboratory medicine.

[12]  C. Tinelli,et al.  Assessment and management of pulmonary alveolar proteinosis in a reference center , 2013, Orphanet Journal of Rare Diseases.

[13]  J. Krischer,et al.  Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. , 2008, American journal of respiratory and critical care medicine.

[14]  E. Pozzi,et al.  Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis For editorial comments see page 503. , 2004, European Respiratory Journal.

[15]  J. Whitsett,et al.  Pulmonary alveolar proteinosis. , 2003, The New England journal of medicine.

[16]  A. Bersten,et al.  PARTITIONING LUNG AND PLASMA PROTEINS: CIRCULATING SURFACTANT PROTEINS AS BIOMARKERS OF ALVEOLOCAPILLARY PERMEABILITY‡ , 1999, Clinical and experimental pharmacology & physiology.

[17]  C Hermans,et al.  Lung epithelium-specific proteins: characteristics and potential applications as markers. , 1999, American journal of respiratory and critical care medicine.

[18]  Y. Hirakata,et al.  Elevation of tumour markers in serum and bronchoalveolar lavage fluid in pulmonary alveolar proteinosis. , 1995, The European respiratory journal.

[19]  T. Ishidate,et al.  [Two cases of pulmonary alveolar proteinosis with increase of serum CEA]. , 1990, Nihon Kyobu Shikkan Gakkai zasshi.

[20]  H. Hansen,et al.  Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer. , 1974, Human pathology.

[21]  L. Teppo,et al.  Pulmonary alveolar proteinosis. , 1966, Annales chirurgiae et gynaecologiae Fenniae.

[22]  S. H. Rosen,et al.  Pulmonary alveolar proteinosis. , 1958, The New England journal of medicine.